Interim analysis of chemo-immunotherapy approach shows improved outcomes.
Interim analysis of chemo-immunotherapy approach shows improved outcomes.
There is growing evidence that combination chemo-immunotherapy improves outcomes for cancer patients. Combining the initial cytotoxic effect of chemotherapy with the immunological effects of ECI®, a vaccine-enhanced adoptive cell therapy, aims to increase overall response and survival rates.
An interim analysis of ELIAS's ongoing study of this combination approach showed that the percent of dogs alive at one year was 64% in the chemo-immunotherapy group compared to 23% in the comparator group, which received four doses of carboplatin and no immunotherapy. The best responders of the combination approach were dogs that received only one dose of carboplatin prior to ECI® where the percent alive at one year was 71%, compared to 21% in the comparator group.
Complete the form to download the oral abstract poster, presented at the 2025 ACVIM Forum on June 19, 2025.